派林生物(000403) - 2024 Q2 - 季度业绩预告

Financial Performance - The net profit attributable to shareholders is expected to be between 31,490 and 34,353 million yuan, representing a year-on-year increase of 120% to 140%[2] - The net profit after deducting non-recurring gains and losses is projected to be between 28,140 and 31,267 million yuan, reflecting a year-on-year growth of 170% to 200%[2] - The basic earnings per share is estimated to be between 0.4309 yuan and 0.4700 yuan, compared to 0.1958 yuan in the same period last year[2] Market Demand and Product Availability - The growth in performance is primarily driven by strong market demand for blood products and an increase in raw plasma collection[3] - The company anticipates an increase in the number and sales volume of available products in the first half of 2024[3] Financial Reporting and Risks - The financial data provided is preliminary and has not been audited by an accounting firm[4] - The specific financial data will be detailed in the company's 2024 semi-annual report[4] - The company emphasizes the importance of investors being aware of investment risks[5]